Differential Expression of Hypoxia Inducible Factor-1 alpha and Tumor Cell Proliferation Between Squamous Cell Carcinomas and Adenocarcinomas Among Operable Non-Small Cell Lung Carcinomas
Abstract:This study aimed to evaluate whether the elevated level of hypoxia-inducible factor-1 (HIF-1 ) correlated with histologic types, angiogenesis, tumor cell proliferation, and clinical parameters in common non-small cell lung carcinomas (NSCLCs). We performed immunohistochemical stains using paraffin-embedded tissue blocks from 84 cases of operable NSCLC [No. of squamous cell carcinoma (SCC), 45; No. of adenocarcinoma (AC), 39]. HIF-1 expression was related with histologic types (66.7% in SCCs vs 20.5% in ACs, p<… Show more
“…However, there was no significant relationship between HIF-1a overexpression and survival of all NSCLC patients. Our findings are supported by those of Lee et al (2003) who showed no association between HIF-1a expression and overall survival in 84 NSCLC patients. In contrast to our results, other groups reported a significant relationship between HIF-1a expression and shorter survival (Swinson et al, 2004;Kim et al, 2005).…”
BACKGROUND: Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC). METHODS: Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome. RESULTS: CAIX tissue overexpression correlated with shorter overall survival (OS) (P ¼ 0.05) and disease-specific survival (DSS) of patients (P ¼ 0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (Po0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (Po0.001) and DSS (Po0.001), mostly in early stage I þ II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P ¼ 0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (Po0.001) in patients with NSCLC. CONCLUSION: High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I þ II carcinomas.
“…However, there was no significant relationship between HIF-1a overexpression and survival of all NSCLC patients. Our findings are supported by those of Lee et al (2003) who showed no association between HIF-1a expression and overall survival in 84 NSCLC patients. In contrast to our results, other groups reported a significant relationship between HIF-1a expression and shorter survival (Swinson et al, 2004;Kim et al, 2005).…”
BACKGROUND: Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC). METHODS: Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome. RESULTS: CAIX tissue overexpression correlated with shorter overall survival (OS) (P ¼ 0.05) and disease-specific survival (DSS) of patients (P ¼ 0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (Po0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (Po0.001) and DSS (Po0.001), mostly in early stage I þ II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P ¼ 0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (Po0.001) in patients with NSCLC. CONCLUSION: High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I þ II carcinomas.
“…This finding is at variance with previous reports (35), although the prognosis after resection of the various histologic subtypes is still a subject of debate (36,37). In the present series, a positive correlation was observed between squamous cell carcinoma histology and EPO-R expression, which can be compared with a previously described association between this histology and hypoxiainduced factor-1a expression (38). The effect of hypoxia and anemia on EPO-R/EPO expression in tumor cells has not been fully evaluated.…”
Purpose:This study was designed to evaluate the prognostic effect of erythropoietin (EPO) and EPO receptor (EPO-R) expression in stage I non^small cell lung cancer (NSCLC) patients. Experimental Design: EPO and EPO-R expression in 158 tumor samples from resected stage I NSCLC was evaluated using immunohistochemistry and tissue array technology. Results: EPO-R and EPO were highly expressed in 20.9% and 35.4% of tumors, respectively. High EPO-R expression compared with negative or low-level expression was associated with a poor 5-year disease-specific survival (60.6% versus 80.8%; P = 0.01, log-rank test). High EPO expression compared with negative and low-level expression was associated with a trend toward a poor 5-year disease-specific survival (69.6% versus 80.4%; P = 0.13, log-rank test). A high level of EPO-R and EPO coexpression was associated with a poor 5-year disease-specific survival compared with other groups of patients (50.0% versus 80.0% survival at the end of follow-up; P = 0.005, log-rank test). In multivariate analysis for disease-specific survival, high-level EPO-R and EPO coexpression was an independent prognostic factor for disease-specific survival (hazard ratio, 2.214; 95% confidence interval, 1.012-4.848; P = 0.046). Conclusion: These results establish the pejorative prognostic value of EPO and EPO-R expression in early-stage resected NSCLC and suggest a potential paracrine and/or autocrine role of endogenous EPO in NSCLC aggressiveness.
“…However, association of HIF-1α with clinicopathological characteristics and prognosis is inconsistent. Previous studies reported that HIF-1α expression in NSCLC was marginally associated with histological types, T-stage and poor prognosis (Lee et al, 2003;Swinson et al, 2004). There are several possible reasons for the inconsistency.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.